Mesenchymal Stem Cell-Based Immunomodulation in Allogeneic Heterotopic Heart-Lung Transplantation
Biancamaria Longoni1*, Erzsèbet Szilàgyi1, Lorenza Puviani2, Benedetta Mazzanti3, Giacomo Timoteo Paoli1, Serena Urbani3, Paola Quaranta1, Sara Antonini1, Sergio Tripodi4, Marcella Cintorino4, Riccardo Saccardi3, Bruno Nardo2 and Franco Mosca1
- *Corresponding Author:
- Prof. Longoni Biancamaria, MD, PhD
Department of Oncology
Transplantation and Advanced Technology in Medicine
University of Pisa, Via Paradisa 2, 56124, Pisa, Italy
E-mail: [email protected]
Received Date: October 08, 2011; Accepted Date: December 12, 2011; Published Date: December 17, 2011
Citation: Longoni B, Szilàgyi E, Puviani L, Mazzanti B, Paoli GT, et al. (2012) Mesenchymal Stem Cell-Based Immunomodulation in Allogeneic Heterotopic Heart-Lung Transplantation. J Transplant Technol Res 2: 107. doi: 10.4172/2161-0991.1000107
Copyright: © 2012 Longoni B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Mesenchymal stem cells are able to differentiate in various cell lineages and they have shown immunomodulatory properties in vitro, altering the cytokine secretion profile of T helper, T effector and dendritic cells and stimulating natural killer cells towards an anti-inflammatory and tolerant phenotype. In vivo they prolong skin allograft survival and may decrease graft-versus-host disease after hematopoietic stem cell transplants. In this work we studied the effects of mesenchymal stem cell treatment in an allogeneic heterotopic heart-lung transplant model.
The following experimental groups were formed: A) Control B) Immunosuppressive therapy (Cyclosporine A) C) Mesenchymal stem-cell intravenous infusion D) Mesenchymal stem-cell infusion plus immunosuppressive treatment.
The infusion of mesenchymal stem cells improved the mean graft survival up to 14.5±3.7 days with respect to the control group (3±0.6 days). Treatment with Cyclosporine A plus mesenchymal stem cells (group D) produced a mean survival time of 18.25±4.9 days, and was not significantly different to the results for group B (21.75±3.5 days). Furthermore, in the immunosuppressive treatment and the mesenchymal stem cell treatment, histological analysis revealed a reduction in the grade of rejection in heart and lung grafts. This decrease was most significant in group D.
In conclusion, mesenchymal stem cells alone or in combination with Cyclosporine A were able to prolong graft survival time. These data suggest that, in vivo, mesenchymal stem cells retain their ability, already shown in vitro, to suppress lymphocyte activation and proliferation.